Provectus Biopharmaceuticals Stock Market Capitalization
| PVCTDelisted Stock | USD 0.11 0.00 0.00% |
Provectus Biopharmaceuticals fundamentals help investors to digest information that contributes to Provectus Biopharmaceutica's financial success or failures. It also enables traders to predict the movement of Provectus OTC Stock. The fundamental analysis module provides a way to measure Provectus Biopharmaceutica's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Provectus Biopharmaceutica otc stock.
Provectus |
Provectus Biopharmaceuticals OTC Stock Market Capitalization Analysis
Provectus Biopharmaceutica's Market Capitalization is the total market value of a company's equity. It is one of many ways to value a company and is calculated by multiplying the price of the stock by the number of shares issued. If a firm has one type of stock its market capitalization will be the current market share price multiplied by the number of shares. However, if a company has multiple types of equities then the market cap will be the total of the market caps of the different types of shares.
Current Provectus Biopharmaceutica Market Capitalization | 44.47 M |
Most of Provectus Biopharmaceutica's fundamental indicators, such as Market Capitalization, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Provectus Biopharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In most publications or references market cap is broken down into the mega-cap, large-cap, mid-cap, small-cap, micro-cap, and nano-cap. Market Cap is a measurement of business as total market value of all of the outstanding shares at a given time, and can be used to compare different companies based on their size.
CompetitionBased on the recorded statements, the market capitalization of Provectus Biopharmaceuticals is about 44.47 M. This is 99.66% lower than that of the Pharmaceuticals sector and 99.06% lower than that of the Health Care industry. The market capitalization for all United States stocks is 99.77% higher than that of the company.
Provectus Market Capitalization Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Provectus Biopharmaceutica's direct or indirect competition against its Market Capitalization to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Provectus Biopharmaceutica could also be used in its relative valuation, which is a method of valuing Provectus Biopharmaceutica by comparing valuation metrics of similar companies.Provectus Biopharmaceutica is currently under evaluation in market capitalization category among its peers.
Provectus Fundamentals
| Return On Asset | -1.85 | ||||
| Operating Margin | (4.77) % | ||||
| Current Valuation | 46.73 M | ||||
| Shares Outstanding | 419.55 M | ||||
| Shares Owned By Insiders | 3.69 % | ||||
| Shares Owned By Institutions | 0.04 % | ||||
| Number Of Shares Shorted | 1.82 M | ||||
| Price To Earning | (0.48) X | ||||
| Price To Book | 5.44 X | ||||
| Price To Sales | 55.94 X | ||||
| EBITDA | (4.56 M) | ||||
| Net Income | (5.54 M) | ||||
| Cash And Equivalents | 84.27 K | ||||
| Total Debt | 2.29 M | ||||
| Debt To Equity | 0.25 % | ||||
| Current Ratio | 0.27 X | ||||
| Book Value Per Share | (0.02) X | ||||
| Cash Flow From Operations | (1.01 M) | ||||
| Short Ratio | 0.47 X | ||||
| Earnings Per Share | (0.01) X | ||||
| Target Price | 3.5 | ||||
| Beta | 0.5 | ||||
| Market Capitalization | 44.47 M | ||||
| Total Asset | 3.51 M | ||||
| Retained Earnings | (180.8 M) | ||||
| Working Capital | 10.6 M | ||||
| Current Asset | 14.72 M | ||||
| Current Liabilities | 4.12 M | ||||
| Z Score | -59.7 | ||||
| Net Asset | 3.51 M |
About Provectus Biopharmaceutica Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Provectus Biopharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Provectus Biopharmaceutica using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Provectus Biopharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. Note that the Provectus Biopharmaceutica information on this page should be used as a complementary analysis to other Provectus Biopharmaceutica's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Other Consideration for investing in Provectus OTC Stock
If you are still planning to invest in Provectus Biopharmaceutica check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Provectus Biopharmaceutica's history and understand the potential risks before investing.
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities |